The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VRCA | -29.24% | -91.51% | -38.92% | -96% |
| S&P | +13.22% | +85.17% | +13.11% | +146% |
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $14.34M | 905.4% |
| Gross Profit | $13.24M | 697.2% |
| Gross Margin | 92.27% | 0.0% |
| Market Cap | $40.71M | -38.4% |
| Market Cap / Employee | $0.57M | 0.0% |
| Employees | 71 | -29.0% |
| Net Income | -$0.27M | 98.8% |
| EBITDA | $1.81M | 109.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $21.10M | -8.1% |
| Accounts Receivable | $7.33M | 8625.0% |
| Inventory | 2.3 | -10.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.58M | -50.9% |
| Short Term Debt | $13.16M | 1033.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -70.48% | 60.2% |
| Return On Invested Capital | -145.98% | -59.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $9.69M | 213.0% |
| Operating Free Cash Flow | $9.69M | 213.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -6.52 | -2.19 | -2.81 | -2.28 | 17.48% |
| Price to Sales | 6.23 | 5.84 | 3.42 | 1.33 | -82.00% |
| Price to Tangible Book Value | -9.37 | -41.16 | -26.19 | -2.28 | -88.25% |
| Enterprise Value to EBITDA | -4.44 | -6.91 | 43.19 | 30.67 | -769.97% |
| Return on Equity | -243.3% | -413.0% | -2059.9% | -1546.6% | 590.20% |
| Total Debt | $45.94M | $42.43M | $38.89M | $35.74M | -24.15% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
